Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
21.83
-0.46 (-2.06%)
Mar 24, 2026, 4:00 PM EDT - Market closed
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
$1,062,350
Profits / Employee
-$45,596
Market Cap
2.71B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 354 | 12 | 3.51% |
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Travere Therapeutics | 497 |
| Tarsus Pharmaceuticals | 370 |
| Dyne Therapeutics | 258 |
| Viridian Therapeutics | 252 |
| Vera Therapeutics | 249 |
ARQT News
- 6 days ago - Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 14 days ago - Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology - GlobeNewsWire
- 19 days ago - Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth - GlobeNewsWire
- 21 days ago - Baron Health Care Fund Q4 2025 Recent Activity - Seeking Alpha
- 21 days ago - Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - GlobeNewsWire
- 25 days ago - Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference - GlobeNewsWire
- 26 days ago - Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case - Seeking Alpha
- 27 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript - Seeking Alpha